A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

Summary

This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19. It is anticipated that approximately 80 patients will be randomized into the study in a 1:1 ratio to 100 mg APX-115 or placebo arm.

Timeline

Start

2021-10-20

Primary completion

2022-04-28

Completion

2022-04-28

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment Challenges”

Drugs

Indications